TABLE 4.
Statistical analyses of effects of pretreatments with BZT analogs on self-administration of R(+)-SKF 81297, (±)-SKF 82958, R(–)-NPA, (–)-quinpirole, and remifentanil as shown in Fig. 4
Comparisons were made in rates of responses on the active lever maintained during each component compared with corresponding components after pretreatments with saline using a two-way repeated-measures ANOVA followed by post-hoc Bonferroni t tests. The post-hoc results are shown only if effects were statistically significant. The Δ values, in responses/second, were calculated as a subtraction of response rates maintained by cocaine after pretreatment with the BZT analog from those obtained after saline pretreatment.
| Treatment | Self-Administered Drug Unit Dose | Pretreatment Dose | Interaction | Post Hoc Tests |
|---|---|---|---|---|
| AHN 1-055 pretreatments (i.p.) | ||||
| R(+)-SKF 81297 self-administration | F4,60 = 12.1; P < 0.001 | F3,60 = 5.17; P = 0.012 | F12,60 = 3.70; P < 0.001 | 3.2 mg/kg (i.p.) at EXT, t = 4.15, P < 0.001 (Δ = +0.109) |
| 3.2 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.), t = 4.47, P < 0.001 (Δ = +0.118) | ||||
| (±)-SKF 82958 self-administration | F4,60 = 12.0; P < 0.001 | F3,60 = 3.44; P = 0.044 | F12,60 = 3.27; P = 0.001 | 3.2 mg/kg (i.p.) at EXT, t = 3.54, P = 0.002 (Δ = +0.156) |
| 3.2 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.), t = 4.20, P < 0.001 (Δ = +0.185) | ||||
| R(–)-NPA self-administration | F4,60 = 6.60; P = 0.001 | F3,60 = 9.48; P < 0.001 | F12,60 = 8.33; P < 0.001 | 3.2 mg/kg (i.p.) at EXT, t = 6.18, P < 0.001 (Δ = +0.101) |
| 3.2 mg/kg (i.p.) at 0.10 µg/kg per inj (i.v.), t = 5.97, P < 0.001 (Δ = +0.097) | ||||
| (–)-Quinpirole self-administration | F4,60 = 3.64; P = 0.022 | F3,60 = 5.48; P = 0.010 | F12,60 = 4.80; P < 0.001 | 3.2 mg/kg (i.p.) at EXT, t = 4.61, P < 0.001 (Δ = +0.169) |
| 3.2 mg/kg (i.p.) at 3.2 µg/kg per inj (i.v.), t = 4.35, P < 0.001 (Δ = +0.159) | ||||
| 10 mg/kg (i.p.) at 32 µg/kg per inj (i.v.), t = 3.41, P = 0.003 (Δ = −0.125) | ||||
| Remifentanil self-administration | F4,60 = 6.87; P = 0.001 | F3,60 = 1.59; P = 0.234 | F12,60 = 3.81; P < 0.001 | 3.2 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.) t = 3.18, P = 0.007 (Δ = −0.096) |
| 3.2 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 4.28, P < 0.001 (Δ = −0.129) | ||||
| 10 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 3.68, P = 0.002 (Δ = −0.111) | ||||
| AHN 2-005 pretreatments (i.p.) | ||||
| R(+)-SKF 81297 self-administration | F4,60 = 13.3; P < 0.001 | F3,60 = 2.28; P = 0.121 | F12,60 = 4.08; P < 0.001 | 1.0 mg/kg (i.p.) at 3.2 µg/kg per inj (i.v.), t = 4.87, P < 0.001 (Δ = +0.045) |
| 10 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 3.94, P = 0.001 (Δ = −0.037) | ||||
| (±)-SKF 82958 self-administration | F4,60 = 12.7; P < 0.001 | F3,60 = 2.38; P = 0.110 | F12,60 = 3.84; P < 0.001 | 1.0 mg/kg (i.p.) at 3.2 µg/kg per inj (i.v.), t = 3.41, P = 0.003 (Δ = −0.024) |
| 10 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 3.97, P = 0.001 (Δ = −0.028) | ||||
| R(–)-NPA self-administration | F4,60 = 6.82; P = 0.001 | F3,60 = 4.85; P = 0.015 | F12,60 = 5.74; P < 0.001 | 1.0 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.), t = 5.85, P < 0.001 (Δ = −0.029) |
| 3.2 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 5.61, P < 0.001 (Δ = +0.028) | ||||
| (–)-Quinpirole self-administration | F4,60 = 3.81; P = 0.018 | F3,60 = 3.19; P = 0.054 | F12,60 = 2.65; P = 0.007 | 1.0 mg/kg (i.p.) at 32 µg/kg per inj (i.v.), t = 4.57, P < 0.001 (Δ = −0.101) |
| 3.2 mg/kg (i.p.) at 32 µg/kg per inj (i.v.), t = 2.74, P = 0.023 (Δ = −0.061) | ||||
| Remifentanil self-administration | F4,60 = 6.78; P = 0.001 | F3,60 = 3.17; P = 0.055 | F12,60 = 2.92; P = 0.003 | 1.0 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.), t = 3.05, P = 0.011 (Δ = −0.077) |
| 1.0 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 3.19, P = 0.007 (Δ = −0.081) | ||||
| 3.2 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 2.97, P = 0.013 (Δ = −0.076) | ||||
| 10 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 5.28, P < 0.001 (Δ = −0.134) | ||||
| JHW 007 pretreatments (i.p.) | ||||
| R(+)-SKF 81297 self-administration | F4,60 = 13.5; P < 0.001 | F3,60 = 8.89; P = 0.001 | F12,60 = 6.88; P < 0.001 | 3.2 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 4.79, P < 0.001 (Δ = +0.049) |
| 10 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 3.04, P = 0.020 (Δ = −0.031) | ||||
| 10 mg/kg (i.p.) at 3.2 µg/kg per inj (i.v.), t = 4.81, P < 0.001 (Δ = −0.049) | ||||
| (±)-SKF 82958 self-administration | F4,60 = 12.4; P < 0.001 | F3,60 = 6.83; P = 0.004 | F12,60 = 4.98; P < 0.001 | 1.0 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 4.99, P < 0.001 (Δ = +0.036) |
| 10 mg/kg (i.p.) at 3.2 µg/kg per inj (i.v.), t = 4.94, P < 0.001 (Δ = −0.036) | ||||
| R(–)-NPA self-administration | F4,60 = 7.51; P < 0.001 | F3,60 = 3.70; P = 0.036 | F12,60 = 4.56; P < 0.001 | 1.0 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.), t = 2.83, P = 0.036 (Δ = −0.015) |
| 3.2 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.), t = 4.37, P < 0.001 = −0.023) | ||||
| 10 mg/kg (i.p.) at 0.32 µg/kg per inj (i.v.), t = 3.35, P = 0.008 (Δ = −0.018) | ||||
| 10 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 4.38, P < 0.001 (Δ = −0.023) | ||||
| (–)-Quinpirole self-administration | F4,60 = 3.51; P = 0.025 | F3,60 = 2.11; P = 0.142 | F12,60 = 1.72; P = 0.086 | |
| Remifentanil self-administration | F4,60 = 7.08; P = 0.001 | F3,60 = 2.42; P = 0.106 | F12,60 = 1.95; P = 0.046 | 1.0 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 3.48, P = 0.006 (Δ = −0.098) |
| 3.2 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 4.22, P < 0.001 (Δ = −0.119) | ||||
| 10 mg/kg (i.p.) at 1.0 µg/kg per inj (i.v.), t = 3.55, P = 0.005 (Δ = −0.100) | ||||